Pet medicine report lookup / Oclacitinib / Dogs

What has been reported to the FDA for Oclacitinib in dogs?

Short answer: The FDA has received 28,973 adverse event reports for dogs that name Oclacitinib. The FDA lists 2 approved animal drug applications containing Oclacitinib for dogs, the earliest approved in 2013. These are counts of reports, not a rate of side effects.
Report counts read · approval records read
Veterinary disclosure Not veterinary advice. A report to the FDA is a suspicion, not proof that a medicine caused an event, and nothing here measures how often a side effect happens. Do not start, stop or change a medicine because of this page. Talk to a licensed veterinarian who knows your animal.
Oclacitinibin dogs
28,973reports to the FDA

The FDA has received 28,973 adverse event reports for dogs that name Oclacitinib.

  1. 28,973 reports name Oclacitinib in dogs, which is 2.9% of all 1,001,380 dog reports. A report counts under every active ingredient it names.
  2. 30% are marked serious and 5.0% record a death or euthanasia; across all dog reports those figures are 29% and 5.4%.
  3. 29% are complaints that the product did not work (38% across all dog reports).
  4. The clinical signs reported most are lack of efficacy, vomiting and ineffective, atopy control.
  5. The FDA lists 2 approved animal drug applications containing Oclacitinib for dogs, the earliest approved in 2013.
  6. None of this is a rate. The FDA data does not record how many dogs were given Oclacitinib, so it cannot say how often any of this happens.

How the reports break down

What the reports sayReportsShare of this medicine's reportsAll dog reports
Marked seriousthe FDA record flags the report as serious8,76630%29%
Death or euthanasiathe outcome recorded in the report, with no finding of cause1,4495.0%5.4%
Did not worka complaint that the product failed to work, which the FDA files as an adverse event8,54429%38%
Seizurea seizure or convulsion is among the clinical signs1,2384.3%4.4%
Not used per labelthe report says the product was not used the way its label directs8,91031%21%

Where on the body do the reported signs sit?

27%16%4.4%3.6%

Not on the body: Did not work 28% Whole body 14% How it was given 2.5%

  1. Did not work28%lack of efficacy, ineffective, atopy control, ineffective, loss of effect, partial lack of efficacy
  2. Stomach and gut27%vomiting, diarrhoea, anorexia, decreased appetite and 2 more
  3. Blood and organ tests16%other abnormal test result, elevated alanine aminotransferase (alt), elevated serum alkaline phosphatase (sap), leucopenia and 1 more
  4. Whole body14%lethargy, lethargy, death by euthanasia, death
  5. Thirst and urination4.4%polydipsia, polyuria
  6. Brain and nerves3.6%seizure
  7. How it was given2.5%overdose
  8. Behaviour2.5%behavioural disorder
  9. Skin and coat1.9%dermal mass

Each figure is a share of sign mentions among the 25 signs reported most for Oclacitinib in dogs. One report can list several signs, so these do not add up to reports. The grouping into body systems is ours; the signs in each group are listed beside it.

Clinical signs reported most

  1. Lack of efficacy3,814 13%
  2. Vomiting3,401 12%
  3. INEFFECTIVE, ATOPY CONTROL2,681 9.3%
  4. Diarrhoea2,324 8.0%
  5. Lethargy2,145 7.4%
  6. INEFFECTIVE, LOSS OF EFFECT1,798 6.2%
  7. Other abnormal test result1,418 4.9%
  8. Elevated alanine aminotransferase (ALT)1,163 4.0%

Reports received per year

3,95202013: 58 reports2014: 1,774 reports2015: 2,665 reports2016: 3,906 reports2017: 3,952 reports2018: 2,403 reports2019: 1,836 reports2020: 1,770 reports2021: 1,335 reports2022: 1,350 reports2023: 1,511 reports2024: 2,467 reports2025: 2,767 reports2026: 1,179 reports2014201620182020202220242026first approved for dogs
More reports in a year can mean more animals treated, a newer product under closer watch, or more people reporting. 2026 is a part year. The tallest bar is 3,952 reports (2017). The earliest FDA approval for dogs was in 2013.

Is it approved for dogs?

DogsFDA-approved product listed
Catsno approved product found
Other animalsnone found
FDA-approved for dogs

The FDA lists 2 approved animal drug applications containing Oclacitinib for dogs, the earliest approved in 2013.

ProductFormApproved forFirst approvedFDA application
ApoquelZoetis Inc.Tablet RXDog2013141-345
Apoquel ChewableZoetis Inc.Chewable Tablets RXDog2023141-555

From the FDA record for Apoquel: APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia.

What can you do next?

What it cost in our price study$124 to $178 at a vet officeApoquel (oclacitinib), 16 mg tablet. The same study recorded $98 at Chewy and $108 at PetMeds. Prices collected April to May 2026; quantity and method are in the study.
Seen a side effect yourself?Report itCall your veterinarian first if your animal is unwell. Then report to the drug maker or to the FDA: the FDA explains both routes. Reports like yours are what this page counts.

Report counts: FDA Center for Veterinary Medicine adverse event reports, read 11 November 2026 (FDA data last updated 5 October 2026). Approvals: Animal Drugs @ FDA, read 11 November 2026. Counts are reports, not animals and not doses.

Where can you go from this result?

This result is one of 94 in the lookup. See Oclacitinib in cats (463 reports). Open it in the lookup to set it beside another medicine, or read how the counts were collected.

To report a suspected side effect in your own animal, follow how to report an animal drug side effect to the FDA. The FDA explains what a report can and cannot show in openFDA's guide to reading the results.

Compiled by Vincent Wesley Couey, PetMaxxing Research (ORCID 0009-0005-6869-308X). Sources: openFDA animal and veterinary adverse event interface; Animal Drugs @ FDA.

☆ Save